Table of Contents
Structure of the Radioactive Pharmaceutical Market
As of 2026, the domestic radioactive pharmaceutical market shows a clearer structure than expected.
This field is not as diverse as ADC or bispecific antibodies and can be summarized into four pillars: Fucare, Selbion, Dukem Bio, and SK Biopharm. However, these companies belong to a common area called theranostics, yet each has different roles.
Fucare and Selbion focus primarily on drug development, while Dukem Bio boasts diagnostic and production infrastructure. Meanwhile, SK Biopharm is solidifying its position as a large latecomer. This article summarizes the characteristics of domestic radioactive pharmaceutical-related stocks and investment perspectives.
Recommended Reads for Bio Stock Investment
Reasons for Fucare's Leading Stock
Fucare is emerging as a notable player in the domestic theranostics sector.
The reason is clear. Fucare has established a closed-loop structure with both diagnostic FC303 and therapeutic FC705 through a PSMA-targeted strategy for prostate cancer.
In this regard, Fucare has positioned itself as a true theranostics company where diagnosis and treatment are organically connected, rather than merely developing therapeutics.
Fucare has numerous strengths. Firstly, it stands out for having both PSMA diagnostic and therapeutic product lines. Additionally, FC705 is conducting Phase 3 clinical trials in Korea and Phase 2a trials in the U.S., gaining attention for its research progression. It is evaluated as one of the leading companies in Korea, close to commercialization.
Moreover, it possesses differentiated competitiveness through second-generation ligands and albumin conjugates. For these reasons, Fucare can be regarded as the most typical yet commercially closest company in Korea's radioactive therapeutic sector. If you are looking for noteworthy stocks in the market currently, this company should be prioritized.
Selbion's Pursuit Points
Selbion is a technology stock trailing Fucare, presenting improved candidates.
The main pipeline under development is Lu-177-DGUL (Focu Botide), aiming for innovative design, not limited to existing PSMA therapeutics.
In particular, it focuses on minimizing exposure to the kidneys and salivary glands through a shorter linker and structural differentiation, which will act as an attractive factor for investors.
Selbion not only shows the commercialization potential of solo therapies but also demonstrates scalability in combination clinical trials with Keytruda.
This is very important. In the case of radioactive pharmaceuticals, a simple single treatment effect may limit the market, and a combination strategy is likely to create greater market opportunities. Selbion has already clearly presented this scalability.
Although its progress may seem somewhat behind Fucare, it has considerable competitiveness as an improved candidate compared to Pluvicto. These factors are expected to lead to positive results in the future market.
Dukem Bio's Infrastructure Strengths
Dukem Bio has a somewhat unique nature. It is more appropriate to view this company as the largest infrastructure company for manufacturing and distributing radioactive pharmaceuticals in Korea, rather than simply as an innovative therapeutic developer.
The radioactive pharmaceutical industry does not end with mere drug design. Success requires a close connection of various factors such as isotope procurement, GMP-certified manufacturing, cold chain management, logistics operations tailored to half-lives, and networks with hospitals.
Dukem Bio has strengths in various respects. It has the overall production and distribution infrastructure, and ample commercialization experience in diagnostic radioactive pharmaceuticals. It holds a firm position in the dementia and Parkinson's disease diagnostics market. Due to its stable value chain, it presents an attractive character for investors.
Therefore, the approach to Dukem Bio should be centered on the value of results and industrial infrastructure rather than aggressive clinical successes. This understanding is more suitable for recognizing it as a key company within the domestic radioactive pharmaceutical ecosystem, distinctly different from rapidly rising new drug stocks.
Variables for SK Biopharm
SK Biopharm is not a specialized radioactive pharmaceutical company but is establishing itself as a noteworthy latecomer.
While competitors in the domestic market focus mainly on Lu-177 based PSMA prostate cancer treatments, SK Biopharm is pursuing a differentiated approach through Ac-225 alpha radioisotope and NTSR1 targeting.
This means it is presenting a new direction distinct from the existing beta radioisotope-centered market structure.
The current phase remains in the early stages. Clinical data is not sufficiently accumulated, and commercialization will take time.
However, considering substantial capital and global development capability, this company is likely to become a key player in the long term.
Although it is difficult to assess based on current performance or clinical progress, its potential to become an important player in the domestic radioactive pharmaceutical market is very high.
Conclusion on Radioactive Pharmaceuticals
It is essential to categorize domestic radioactive pharmaceutical-related stocks based on their respective roles.
The key player is Fucare, while Selbion stands out as a following stock with technological differentiation and combination expansion potential. Dukem Bio serves as a stable benefiting stock based on its robustness, and SK Biopharm is establishing its position as a latecomer from a long-term perspective.
Understanding the characteristics of each stock will aid in investment decisions.
Looking at the current market structure, ADC still holds a larger proportion of commercialization revenue than radioactive pharmaceuticals. However, radioactive pharmaceuticals are rapidly expanding their influence in terms of growth rate and strategic importance.
In conclusion, while the current market situation shows that ADC is on a larger scale, radioactive pharmaceuticals are demonstrating more rapid development. This analysis will help in understanding future market outlooks.
Currently, Fucare is the most remarkable player among theranostics-related stocks in the domestic stock market. Following closely are Selbion and Dukem Bio, while SK Biopharm is positioned as a promising candidate in the long term.
※ This article is for personal record and information sharing purposes, not an investment recommendation. It does not advocate the purchase or sale of any specific assets or stocks.
#RadioactivePharmaceuticals, #Theranostics, #RadioactivePharmaceuticalStocks, #Fucare, #Selbion, #DukemBio, #SKBiopharm, #PSMA, #ProstateCancerTherapeutics, #NuclearMedicine, #RPT, #Lu177, #Ac225, #AlphaRadioisotope, #BetaRadioisotope, #DiagnosticTherapeuticLinkage, #BioInvestment, #BioRelatedStocks, #DomesticBioStocks, #PharmaceuticalBio, #NewDrugDevelopment, #PharmaceuticalInvestment, #RadioactiveTherapeutics, #DiagnosticPharmaceuticals, #GMPProduction, #BioMarketAnalysis, #TheranosticsRelatedStocks, #BioGrowthStocks, #MedicalInnovation, #DomesticStockMarket
Frequently Asked Questions (FAQ)
Q. How is the domestic radioactive pharmaceutical market structured?
The domestic market is classified into four pillars: Fucare, Selbion, Dukem Bio, and SK Biopharm.
As of 2026, the domestic radioactive pharmaceutical market has formed a clear structure centered around the four companies: Fucare, Selbion, Dukem Bio, and SK Biopharm. All of these belong to the field of theranostics, but each has different roles. Fucare and Selbion focus on therapeutic development, while Dukem Bio has manufacturing and distribution infrastructure, and SK Biopharm is pursuing a differentiated technological approach as a latecomer. This structure anticipates various roles and growth prospects within the market.
Q. Why is Fucare gaining attention in the radioactive pharmaceutical market?
Because they have established a closed-loop system for PSMA-targeted diagnosis and treatment for prostate cancer.
Fucare simultaneously possesses diagnostic FC303 and therapeutic FC705 targeting PSMA (prostate cancer), forming a closed-loop structure where diagnosis and treatment are organically connected. Notably, FC705 is concurrently undergoing Phase 3 trials in Korea and Phase 2a trials in the U.S., and it has secured competitiveness through second-generation ligands and albumin conjugate technology. This places Fucare as one of the most characteristic and commercially close firms in the domestic radioactive therapeutic field.
Q. What are Selbion's characteristics and advantages in radioactive pharmaceutical development?
Expectations for reduced side effects and market expansion through Lu-177-DGUL and combination clinical trials.
Selbion is a technology stock following Fucare, developing Lu-177-DGUL (Focu Botide). This candidate minimizes drug exposure in the kidneys and salivary glands through a shorter linker structure and focuses on reducing side effects, also showing potential for expansion through combination clinical trials with Keytruda. Although its clinical progress may seem somewhat slower than Fucare's, it is considered a competitively improved candidate compared to Pluvicto.
Q. What role and strengths does Dukem Bio possess in the radioactive pharmaceutical market?
Holds the largest manufacturing and distribution infrastructure in Korea and has a strong position in the diagnostic pharmaceutical market.
Dukem Bio is focused on building production and distribution infrastructure rather than simple therapeutic development. It has a stable value chain equipped with isotope procurement, GMP manufacturing, cold chain operations, and hospital networks, particularly securing a strong market position in radioactive pharmaceuticals for dementia and Parkinson's disease diagnostics. Therefore, it is appropriate to evaluate Dukem Bio based on stable results and infrastructure value rather than aggressive clinical outcomes.
Q. What are the differentiating factors and outlook for SK Biopharm's radioactive pharmaceutical business?
Focuses on Ac-225 alpha radioisotope and NTSR1 targeting, with a high potential for long-term growth.
SK Biopharm is not a specialized radioactive pharmaceutical enterprise, but it is developing Ac-225 alpha radioisotope and NTSR1-targeted therapies as a major latecomer. This is a differentiated strategy, diverging from the previous competitors focusing on Lu-177 beta radioisotope and PSMA targets. Presently, the clinical and commercialization stages are in their infancy, but with substantial capital and global capabilities, there is a high potential for SK Biopharm to grow as an important player in the domestic market over the long term.
Q. How should investments in radioactive pharmaceutical-related stocks be approached?
A differentiated investment strategy should be established based on the roles and technological characteristics of each company.
Radioactive pharmaceutical related stocks have distinct roles. Fucare is a leading stock in the diagnostic-therapeutic linkage commercialization, Selbion is a following stock undergoing technological improvements and expanding combination therapies, Dukem Bio is a stable beneficiary stock based on its infrastructure, and SK Biopharm is a latecomer with potential for future growth. Investors should understand these characteristics and consider initial clinical status, technological state, infrastructure stability, and long-term growth potential when constructing their portfolios.
